STTK — Shattuck Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1680367 ·
Last close
$7.90
Market Cap
$792.87M
52W High
$8.02
52W Low
$3.33
ADV30
1,129,366
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,545,000 | -14,767,000 | 102,121,000 | 90,419,000 | 6,286,000 |
| Dec 2025 | 0 | — | -13,371,000 | -12,593,000 | 91,026,000 | 54,192,000 | 8,636,000 |
| Sep 2025 | 1,000,000 | — | -10,716,000 | -10,056,000 | 100,333,000 | 42,548,000 | 7,093,000 |
| Jun 2025 | 0 | — | -13,032,000 | -12,458,000 | 64,371,000 | 50,467,000 | 7,352,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,274,000
Investing CF
$361,000
Financing CF
$70,434,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-445,296,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-52,664,000
Pretax Income TTM
$-49,874,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000,000
EBITDA
$-52,140,000
Free Cash Flow
$-21,216,624
Enterprise Value
$550,106,304
Total Cash
$208,303,008
Total Debt
$2,674,000
Shares Out
100,363,253
Trailing EPS
$-0.44
Book Value
$1.27
ROE
-39.2%
ROA
-24.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,000,000 | -51,508,000 | -48,809,000 | 91,026,000 | 8,636,000 | — | -39,882,000 |
| Dec 2024 | 5,721,000 | -80,567,000 | -75,410,000 | 91,049,000 | 11,423,000 | — | -60,515,000 |
| Dec 2023 | 1,657,000 | -91,957,000 | -87,298,000 | 159,564,000 | 14,859,000 | — | -81,228,000 |
| Dec 2022 | 652,000 | -103,329,000 | -101,945,000 | 205,324,000 | 29,167,000 | — | -94,498,000 |
TTM Snapshot
Revenues TTM
$5,795,000
NetIncome TTM
$-86,261,000
OpCashFlow TTM
$0
Assets (Latest)
$91,049,000
Forward EPS
$-0.52
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $7.90 · call volume: 100 · put volume: 325
Expected Move to 2026-12-18:
±$3.21
(40.70%) —
implied range
$4.69 –
$11.12
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NGNE | Neurogene Inc. | $793.25M | $39.64 | — |
| NVCT | Nuvectis Pharma, Inc. | $777.72M | $23.87 | — |
| PHAR | Pharming Group N.V. | $811.12M | $11.46 | — |
| SLN | Silence Therapeutics plc | $826.03M | $13.29 | — |
| CYRX | Cryoport, Inc. | $827.61M | $16.34 | — |
News headlines (Yahoo Finance, 1h cache)
What Shattuck Labs Stock Topped the Market on Monday
2026-08-24 22:23 · Yahoo
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
2026-08-13 13:55 · Yahoo
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-11 10:15 · Yahoo
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
2026-07-24 22:27 · Yahoo
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
2026-06-09 12:00 · Yahoo
Shattuck Labs Announces Phase 1 Results for SL-325
2026-06-08 10:00 · Yahoo
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
2026-06-05 20:05 · Yahoo
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
2026-05-11 11:33 · Yahoo
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 10:15 · Yahoo
Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)
2026-05-01 08:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.